Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-05-21
Schrödinger, Inc.
Schrödinger sells molecular design software and discovery workflow tools to pharma, biotech, industrial, and academic customers, and also monetizes collaborative and proprietary drug programs.
ai biotech cloud healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From modeling tools to discovery workflow control
The upside depends less on a blockbuster internal drug and more on becoming the trusted operating layer for pharma discovery teams. If hosted delivery, Bunsen, and workflow governance deepen account penetration, revenue can more than double and the stock can rerate from a depressed base.

Analysis

Thesis
The 5-year upside is a workflow-quality upgrade, not a heroic biotech bet: if hosted delivery, LiveDesign, and Bunsen turn Schrödinger into a governed discovery operating layer, it can capture more throughput and trust value per account while partnered drug economics preserve upside without forcing a balance-sheet-heavy pipeline build.
Last Economy Alignment
Cheaper cognition and compute should expand discovery throughput, and Schrödinger has real workflow embedment and switching costs through LiveDesign. But it does not own a hard industry standard, so generic agents and lower-cost modeling alternatives can still compress pricing if the company fails to control the governed workflow layer.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside comes from becoming system-of-record software for discovery work rather than remaining a respected modeling toolkit. If hosted workflows, Bunsen, and trust-heavy enterprise features deepen usage inside major pharma accounts, revenue quality should improve, customer expansion should broaden, and the market can value the business more like durable scientific workflow software with biotech option value attached.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is strategic proof, not solvency. If hosted migration and Bunsen deepen workflow control, Schrödinger can capture more value per customer; if generic agents sit above interchangeable tools, pricing compresses and the company remains a lumpy hybrid of niche software and option-like biotech.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.60
They help drug teams run more design cycles as AI and compute get cheaper, and they already sit inside real discovery workflows. The advantage is their trusted workflow hub and validated science, but generic AI agents could still sit on top and squeeze pricing if they do not own the governed system of record.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.88
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case